Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, May 18, 2013
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

T cell response to cholera infection
Weil AA, Arifuzzaman M, Bhuiyan TR, Harris JB, Kendall EA, Hossain A, LaRocque RC, Harris AM, Tarique AA, Chowdhury F, Khan AI, Banerjee KK, Ryan ET, Qadri F, Calderwood SB

Natural Vibrio cholerae infection generates a robust B-cell response that wanes for T-cell independent antigens, suggesting that B-cell responses may be mediated in a T-cell dependent manner. Patients with cholera develop a memory-effector T-cell response to cholera antigens, and B-cell activation occurs after T-cell population expansion, suggesting that T-cells may play an important role in the development and maintenance of memory B-cell responses to T-cell dependent antigens.

A Novel Multiplexed Digital Gene Expression Technology
Gary K. Geiss1,#, Roger Bumgarner2, Brian Birditt1, Timothy Dahl1, Naeem Dowidar1, Dwayne L. Dunaway1, H. Perry Fell1, Sean Ferree1, Renee D. George1, Tammy Grogan1, Jeffrey J. James1, Malini Maysuria1, Jeffrey D. Mitton1, Paola Oliveri4, Jennifer L. Osborn3, Tao Peng2, Amber L. Ratcliffe1, Philippa J. Webster1, Eric H. Davidson4, and Leroy Hood5

We describe a novel platform, the nCounter Analysis System, for sensitive, highly multiplexed, digital gene expression analysis based on NanoString’s novel molecular barcoding technology. Detection of individual mRNA molecules using an assigned sequence of six different fluorescent spots per probe are detected, and then the number of times that code sequence appears in a sample are counted.

miRNAs in Treating Cardiomyopathy
Veenu Aishwarya

The study aims to design antigomirs against miRNAs involved in Cardiomyopathy. Potential miRNAs involved in the down regulation of certain important genes during this disorder have been identified. All reported miRNAs were scanned using an algorithm against these genes. At three step protocol was followed to take care of false positives and false negatives. Further, HL-1 cells (cardiomyocytes) are been transfected by anti-miRNAs for confirmation.

Targeting Inflammatory Cytokines Using Adenoviruses: gene delivery of biological therapies in ovarian cancer
Michael A. Salako, Hagen Kulbe, Iain A. McNeish, Frances R. Balkwill

Constitutive TNF-alpha expression is characteristic of the malignant ovarian surface epithelium. Adenoviral mutants hold great promise as gene therapy vectors but their efficacy is hindered by an inflammatory cascade orchestrated by TNF-alpha. We found that delivering TNF-alpha shRNA to ovarian cancer cells using oncolytic adenoviruses could reduce the inflammatory cascade generated by adenoviruses and also had direct anti-tumour activity on the cancer cells.

Use of gamma scinitigraphy to understand inhaled device/formulation variables on delivery efficiency and
Peter Scholes and Karen Jones

Systemic delivery of both small molecules and macromolecules via inhaled therapies is an area of significant ongoing research1. The pulmonary route offers the physiological benefits of a highly vascularised, large surface area for absorption which can promote high bioavailability and a rapid onset of action. For biomolecules such as peptides, proteins and nucleic acid derivatives, inhaled drug delivery can also provide a viable alterative to intravenous administration.

Quantifying the Impact of a Drug on Gastric Emptying: Measuring the Pharmacodynamic Effect in Clinical Trials
A Rankin, M Paterson, A Connor

Many drug classes are known to alter the rate of gastric emptying. Whilst there is no specific regulatory guidance requiring the impact of drugs on GE to be measured, it is important to fully understand the mode of action and the relationship between the pharmacokinetic profile and the pharmacodynamic response.

Building Flexibility ino Phase I Protocols and Early Clinical Development Programs
Lloyd Stevens and Gareth King

The transition of a drug candidate into Phase I and other early drug development programs is undergoing considerable examination and change. This has largely been brought about by commercial and scientific drivers to reduce attrition rates coupled with an evolving regulatory environment, all of which encourage the pharmaceutical industry to build both scientific focus and flexibility into the drug development program.

Evaluation of Human Regional Bioavailability to Assess Whether Modified Release Development is Feasible
A Connor, G King and K Jones

Many modified release (MR) oral formulations rely on bioavailability from the distal regions of the gastrointestinal (GI) tract (i.e. the ileum and colon). Therefore, by assessing the bioavailability of a drug following delivery to the distal intestines, it is possible to determine whether MR formulation development is achievable.

THE OSTEOPROTECTIVE ACTION OF 6-OXA-8a-ANALOGUES OF STEROID ESTROGENS
A.G. Shavva, V.N. Belov, A.Yu. Solovyev, S.N. Morozkina

We synthesized fourteen 6-oxa-8a-estrogens analogues and investigated osteoprotective and uterotropic actions. We demonstrated correlation: every modification in structure of 6-oxa-8-analogues leading to strong (>30%) reduction of uterotropic action induces slump of osteoprotective activity. This allows to make conclusion: main biotarget, responsible for appearance of osteoprotective action is a-estrogen receptor. We found steroid estrogen analogues with cholesterol-lowering properties without u

<< 1 2 3 4 >>
Showing Results 21 - 30 of 35
Scientific News
Results of the ROTAVAC Rotavirus Vaccine Study in India
Statement of Anthony S. Fauci, M.D. Director, National Institute of Allergy and Infectious Diseases National Institutes of Health.
Vince and Associates Clinical Research Joins the Altasciences Group
The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
Cocaine Vaccine Passes Key Testing Hurdle
New anti-cocaine vaccine research shows drug can't reach the brain, human clinical trials on the horizon.
Redx Pharma Opens £10.5 Million R&D Centre in UK
Liverpool-based drug discovery and development company Redx Pharma is to open a new research and development facility at AZ's Alderley Park site in Cheshire.
NIH Clinical Trial Begins for Treatment of Rare, Fatal Neurological Disorder
Government, industry, academia, and patient groups collaborate on Niemann-Pick Type C research.
NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial
The trial results appeared in the April 1 issue of the Journal of Infectious Diseases.
Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer
GLPG1790 has high efficacy against triple-negative breast cancer.
Genticel Announces Positive Data from Phase I Trial in HPV Infected Women
First ever trial to recruit HPV infected women with no cervical lesions.
Nanosponges can Remove Toxins from Bloodstream
Engineers have invented a “nanosponge” capable of safely removing a broad class of dangerous toxins from the bloodstream.
Results from C3BS C-CURE® Trial Published in the Journal of the ACC
Trial demonstrates statistically significant improvements in heart function and exercise tolerance with cardiopoietic stem cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net